Title:
HETEROAROMATIC ACETAMIDE DERIVATIVE, AND PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/244460
Kind Code:
A1
Abstract:
Provided in the present invention are a heteroaromatic acetamide derivative and the preparation and the use thereof, wherein the heteroaromatic acetamide derivative is a heteroaromatic acetamide compound as shown in general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. According to the present invention, experiments have confirmed that the heteroaromatic acetamide derivative of the present invention can specifically bind to transient receptor potential ankyrin 1 (TRPA1) and inhibit or reduce the activity thereof, and can be used for treating diseases mediated by TRPA1. The present invention further provides a method for preparing the heteroaromatic acetamide derivative, and a drug and pharmaceutical composition containing the heteroaromatic acetamide derivative.
More Like This:
Inventors:
CHENG YUNFENG (CN)
HU YONGZHOU (CN)
HU YONGZHOU (CN)
Application Number:
PCT/CN2020/093277
Publication Date:
December 10, 2020
Filing Date:
May 29, 2020
Export Citation:
Assignee:
HANGZHOU WESTAN PHARMACEUTICAL TECH CO LTD (CN)
International Classes:
A61K31/495; C07D295/185; A61P25/04
Domestic Patent References:
| WO2006010968A1 | 2006-02-02 |
Foreign References:
| EP1736465A1 | 2006-12-27 | |||
| CN1230431C | 2005-12-07 | |||
| CN110357833A | 2019-10-22 |
Other References:
KE-WEI LIANG, KANG WANG, FEN CAI, KAI-DI MEI, YUAN-YUAN WANG, JING YAO: "Development and Research Progress of Drug Targeting TRPA1 Channel", PROGRESS IN MODERN BIOMEDICINE, vol. 5, no. 19, 1 March 2019 (2019-03-01), pages 996 - 1000, XP055765670, DOI: 10.13241/j.cnki.pmb.2019.05.045
CHENHACKOS, NAUNYN- SCHMIEDEBERGS ARCH PHARMACOL, vol. 388, 2015, pages 451 - 463
MUKHOPADHYAY ET AL., PHARMACEUTICALS, vol. 9, no. 70, 2015, pages 1 - 11
MACPHERSON ET AL., NATURE, vol. 445, no. 7127, 2007, pages 541 - 5
CHENHACKOS, NAUNYN-SCHMIEDEBERGS ARCH PHARMACOL, vol. 388, 2015, pages 451 - 463
ZURBORG ET AL., NAT NEUROSCI, vol. 10, no. 3, 2007, pages 277 - 9
BAUTISTA ET AL., PROC NATL ACAD SCI USA, vol. 102, no. 34, 2005, pages 12248 - 52
OBATA ET AL., J CLIN INVEST, vol. 115, no. 9, 2005, pages 2393 - 401
MCNAMARA ET AL., PROC NATL ACAD SCI USA, vol. 104, no. 33, 2007, pages 13525 - 30
BENEMEI ET AL., BR J PHARMACOL, vol. 171, no. 10, 2014, pages 2552 - 67
YANGLI, MED SCI MONIT, vol. 22, 2016, pages 2917 - 2923
CACERES ET AL., PROC NATL ACAD SCI USA., vol. 106, no. 22, 2009, pages 9099 - 104
ANDRE ET AL., BR J PHARMACOL, vol. 158, 2009, pages 1621 - 1628
LAVINKA ET AL., COUGH, vol. 9, no. 1, 2013, pages 8
NASSINI ET AL., PLOS ONE, vol. 7, 2012, pages e42454
KONDO ET AL., DIGESTION, vol. 82, no. 3, 2010, pages 150 - 5
CATTARUZZA ET AL., AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 298, no. 1, 2010, pages G81 - 91
WILSON ET AL., NAT NEUROSCI, vol. 14, no. 5, 2011, pages 595 - 602
MCGARAUGHTY ET AL., MOL PAIN, vol. 6, 2010, pages 14
TREVISAN ET AL., CANCER RES., vol. 73, no. 10, 2013, pages 3120 - 31
LEE ET AL., BR J PHARMACOL, vol. 153, no. 8, 2008, pages 1739 - 1749
CHEN ET AL., PAIN, vol. 152, no. 5, 2011, pages 1165 - 72
AMBRUS ET AL., J CELL AND MOL MED, vol. 19, no. 12, 2015, pages 2771 - 9
CHENHACKOS, NAUNYN- SCHMIEDEBERGS ARCH PHARMACOL, vol. 388, 2015, pages 451 - 463
MUKHOPADHYAY ET AL., PHARMACEUTICALS, vol. 9, no. 70, 2015, pages 1 - 11
MACPHERSON ET AL., NATURE, vol. 445, no. 7127, 2007, pages 541 - 5
CHENHACKOS, NAUNYN-SCHMIEDEBERGS ARCH PHARMACOL, vol. 388, 2015, pages 451 - 463
ZURBORG ET AL., NAT NEUROSCI, vol. 10, no. 3, 2007, pages 277 - 9
BAUTISTA ET AL., PROC NATL ACAD SCI USA, vol. 102, no. 34, 2005, pages 12248 - 52
OBATA ET AL., J CLIN INVEST, vol. 115, no. 9, 2005, pages 2393 - 401
MCNAMARA ET AL., PROC NATL ACAD SCI USA, vol. 104, no. 33, 2007, pages 13525 - 30
BENEMEI ET AL., BR J PHARMACOL, vol. 171, no. 10, 2014, pages 2552 - 67
YANGLI, MED SCI MONIT, vol. 22, 2016, pages 2917 - 2923
CACERES ET AL., PROC NATL ACAD SCI USA., vol. 106, no. 22, 2009, pages 9099 - 104
ANDRE ET AL., BR J PHARMACOL, vol. 158, 2009, pages 1621 - 1628
LAVINKA ET AL., COUGH, vol. 9, no. 1, 2013, pages 8
NASSINI ET AL., PLOS ONE, vol. 7, 2012, pages e42454
KONDO ET AL., DIGESTION, vol. 82, no. 3, 2010, pages 150 - 5
CATTARUZZA ET AL., AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 298, no. 1, 2010, pages G81 - 91
WILSON ET AL., NAT NEUROSCI, vol. 14, no. 5, 2011, pages 595 - 602
MCGARAUGHTY ET AL., MOL PAIN, vol. 6, 2010, pages 14
TREVISAN ET AL., CANCER RES., vol. 73, no. 10, 2013, pages 3120 - 31
LEE ET AL., BR J PHARMACOL, vol. 153, no. 8, 2008, pages 1739 - 1749
CHEN ET AL., PAIN, vol. 152, no. 5, 2011, pages 1165 - 72
AMBRUS ET AL., J CELL AND MOL MED, vol. 19, no. 12, 2015, pages 2771 - 9
Attorney, Agent or Firm:
SHANGCHENG & PARTNERS (CN)
Download PDF: